Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Clin Invest. 2013 Feb 1;123(2):563-5. doi: 10.1172/JCI67460. Epub 2013 Jan 25.

B4 androgen ablation: attacking the prostate cancer stem cell.

Author information

  • 1University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, Room 6302, Ann Arbor, Michigan 48109, USA. mwicha@umich.edu

Abstract

There is increasing evidence that prostate cancers in rodent models and in men contain a cellular subpopulation that displays stem cell properties. These prostate cancer stem cells (PCSCs) lack androgen receptor expression and are increased in castration-resistant disease. In this issue of the JCI, a study from Yoshioka et al. demonstrates that PCSCs are regulated by a pathway in which α6β4 integrin amplifies signaling through ErbB2 and c-Met receptors. Targeting this pathway provides a novel therapeutic strategy for hormone refractory prostate cancer.

Comment on

PMID:
23348735
[PubMed - indexed for MEDLINE]
PMCID:
PMC3561837
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Journal of Clinical Investigation Icon for PubMed Central
    Loading ...
    Write to the Help Desk